AAAAAA
Results:
1-10
|
Results: 10
Authors:
Van Cutsem, E
Dicato, M
Wils, J
Citation: E. Van Cutsem et al., Recent advances in the management of colorectal cancer, EUR J CANC, 37(18), 2001, pp. 2302-2309
Authors:
Duffaud, F
van der Burg, MEL
Namer, M
Vergote, I
Willemse, PHB
Huinink, WT
Guastalla, JP
Nooij, MA
Kerbrat, P
Piccart, M
Tumolo, S
Favalli, G
van der Vange, N
Lacave, AJ
Wils, J
Splinter, TAW
Einhorn, N
Roozendaal, KJ
Rosso, R
Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
Authors:
Wils, J
Citation: J. Wils, Repetita iuvant - INTACC (Intergruppo Italiano Terapia Adiuvante Carcinomadel Colon) - Reply, ANN ONCOL, 12(9), 2001, pp. 1331-1331
Authors:
Wils, J
O'Dwyer, P
Labianca, R
Citation: J. Wils et al., Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives, ANN ONCOL, 12(1), 2001, pp. 13-22
Authors:
Lorenz, M
Heinrich, S
Staib-Sebler, E
Kohne, CH
Wils, J
Nordlinger, B
Encke, A
Citation: M. Lorenz et al., Regional chemotherapy in the treatment of advanced pancreatic cancer - is it relevant?, EUR J CANC, 36(8), 2000, pp. 957-965
Authors:
Dicato, M
Van Cutsem, E
Wils, J
Citation: M. Dicato et al., Perspectives in colorectal cancer - Introduction, SEMIN ONCOL, 27(5), 2000, pp. 1-1
Authors:
Van Cutsem, E
Cunningham, D
Huinink, WWT
Punt, CJA
Alexopoulos, CG
Dirix, L
Symann, M
Blijham, GH
Cholet, P
Fillet, G
Van Groeningen, C
Vannetzel, JM
Levi, F
Panagos, G
Unger, C
Wils, J
Cote, C
Blanc, C
Herait, P
Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59
Authors:
Wils, J
van Geuns, H
Stoot, J
Bergmans, M
Boschma, F
Bron, H
Degen, J
Erdkamp, F
van Erp, J
Haest, J
Iding, R
Lalisang, F
de Pree, N
de Rooy, C
Snijders, M
Schepers, J
Vreeswijk, J
Wals, J
Werter, M
Wetzels, L
Smeets, J
Schouten, L
Citation: J. Wils et al., Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial ofthe Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg, ANTI-CANC D, 10(3), 1999, pp. 257-261
Authors:
Klinkenbijl, JH
Jeekel, J
Sahmoud, T
van Pel, R
Couvreur, ML
Veenhof, CH
Arnaud, JP
Gonzalez, DG
de Wit, LT
Hennipman, A
Wils, J
Citation: Jh. Klinkenbijl et al., Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region - Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group, ANN SURG, 230(6), 1999, pp. 776-782
Authors:
Meunier, F
Torfs, K
Hildebrand, J
Piccart, M
Otten, J
Wils, J
Hall, R
Pecorelli, S
Lefebvre, J
Willemze, A
De Pauw, B
Noordijk, E
Eggermont, A
Tursz, T
Chevallier, B
Tirelli, U
Monfardini, S
Giaccone, G
Bartelink, H
Kaasa, S
Citation: F. Meunier et al., Cost evaluation of treatment modalities in cancer patients, BIOM HLTH R, 24, 1998, pp. 362-369
Risultati:
1-10
|